Report Overview

The global sepsis and septic shock market size stood at around USD 3.5 billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period

Sepsis is a potentially life-threatening complication due to the presence of both infection and the systemic inflammatory response; it is caused by an overwhelming immune response to infection. Sepsis is treated as a medical emergency, and severe cases of sepsis may lead to septic shock, in which blood pressure reduces dramatically. It is estimated that the sepsis and septic shock treatment market will show significant market growth over the forecast period primarily due to the growing number of target population, higher number of unmet needs, advancement in sepsis assessment techniques, and presence of novel pipeline therapeutics



Market Growth Drivers

The most important driver of growth in the sepsis and septic shock marketplace will be the arrival of the first therapies targeting specific segments of the sepsis population

An aging population is one of the dominant factors in the increased incidence rate of sepsis and septic shock during the forecast period

Innovations in R&D strategies and the implementation of adaptive clinical trial designs that feature long-term all-cause mortality outcomes will continue to drive the launch of clinical pipeline drugs throughout the forecast period

Improvements in the management of sepsis and septic shock patients will result in decreased mortality rates and an increased number of patients in need of immunostimulatory or immunosuppressive treatment options to restore immune homeostasis

The launch of Asahis thrombomodulin will foster increased participation in the development pipeline of novel sepsis and septic shock therapies

Continued awareness campaigns of sepsis and septic shock at the national and international levels will result in earlier diagnosis and improved outcomes for patients